Evaluation of newborn sickle cell screening programme in England: 2010-2016
File(s)
Author(s)
Type
Journal Article
Abstract
Objective To evaluate England’s NHS newborn sickle cell screening programme performance in children up to the age of 5 years.
Design Cohort of resident infants with sickle cell disease (SCD) born between 1 September 2010 and 31 August 2015 and followed until August 2016.
Participants 1317 infants with SCD were notified to the study from all centres in England and 1313 (99%) were followed up.
Interventions Early enrolment in clinical follow-up, parental education and routine penicillin prophylaxis.
Main outcome measures Age seen by a specialist clinician, age at prescription of penicillin prophylaxis and mortality.
Results All but two resident cases of SCD were identified through screening; one baby was enrolled in care after prenatal diagnosis; one baby whose parents refused newborn screening presented symptomatically. There were 1054/1313 (80.3%, 95% CI 78% to 82.4%) SCD cases seen by a specialist by 3 months of age and 1273/1313 (97%, 95% CI 95.9% to 97.8%) by 6 months. The percentage seen by 3 months increased from 77% in 2010 to 85.4% in 2015. 1038/1292 (80.3%, 95% CI 78.1% to 82.5%) were prescribed penicillin by 3 months of age and 1257/1292 (97.3%, 95% CI 96.3% to 98.1%) by 6 months. There were three SCD deaths <5 years caused by invasive pneumococcal disease (IPD) sensitive to penicillin.
Conclusion The SCD screening programme is effective at detecting affected infants. Enrolment into specialist care is timely but below the programme standards. Mortality is reducing but adherence to antibiotic prophylaxis remains important for IPD serotypes not in the current vaccine schedule.
Design Cohort of resident infants with sickle cell disease (SCD) born between 1 September 2010 and 31 August 2015 and followed until August 2016.
Participants 1317 infants with SCD were notified to the study from all centres in England and 1313 (99%) were followed up.
Interventions Early enrolment in clinical follow-up, parental education and routine penicillin prophylaxis.
Main outcome measures Age seen by a specialist clinician, age at prescription of penicillin prophylaxis and mortality.
Results All but two resident cases of SCD were identified through screening; one baby was enrolled in care after prenatal diagnosis; one baby whose parents refused newborn screening presented symptomatically. There were 1054/1313 (80.3%, 95% CI 78% to 82.4%) SCD cases seen by a specialist by 3 months of age and 1273/1313 (97%, 95% CI 95.9% to 97.8%) by 6 months. The percentage seen by 3 months increased from 77% in 2010 to 85.4% in 2015. 1038/1292 (80.3%, 95% CI 78.1% to 82.5%) were prescribed penicillin by 3 months of age and 1257/1292 (97.3%, 95% CI 96.3% to 98.1%) by 6 months. There were three SCD deaths <5 years caused by invasive pneumococcal disease (IPD) sensitive to penicillin.
Conclusion The SCD screening programme is effective at detecting affected infants. Enrolment into specialist care is timely but below the programme standards. Mortality is reducing but adherence to antibiotic prophylaxis remains important for IPD serotypes not in the current vaccine schedule.
Date Issued
2018-07-01
Date Acceptance
2017-09-25
Citation
Archives of Disease in Childhood, 2018, 103 (7), pp.648-653
ISSN
0003-9888
Publisher
BMJ Publishing Group
Start Page
648
End Page
653
Journal / Book Title
Archives of Disease in Childhood
Volume
103
Issue
7
Copyright Statement
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/
This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/
License URL
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000439840700007&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Subjects
Science & Technology
Life Sciences & Biomedicine
Pediatrics
INVASIVE PNEUMOCOCCAL DISEASE
CONJUGATE VACCINE
PENICILLIN PROPHYLAXIS
CHILDREN
MORTALITY
ANEMIA
SEPTICEMIA
SURVIVAL
OUTCOMES
COHORT
Publication Status
Published
Date Publish Online
2017-11-05